Helicobacter pylori infection leads to chronic gastritis and increased risk of gastric cancer.
40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks.
Osiris Therapeutics announced it has stopped a study of its Grafix cellular wound care product in Diabetic Foot Ulcer because...
We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms.
This is a 3-part study. Part A and B have identical designs and are randomized, double-blinded, placebo-controlled studies, which will include patients with eosinophilic gastritis and/or duodenal-only disease.
A new comparative effectiveness analysis, published online in Wound Repair & Regeneration, reported that Apligraf, from Novartis, has demonstrated improved...
Adocia announced topline results from a Phase III clinical trial of BioChaperone PDGF (BC PDGF) in the treatment of diabetic...
PARIET tablets are indicated for the treatment of: • Active duodenal ulcer. • Active benign gastric ulcer. • Symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD). • Gastro-Oesophageal Reflux Disease Long-term Management (GORD Maintenance). • Symptomatic treatment of moderate to very severe gastro-oesophageal reflux disease (symptomatic GORD). • Zollinger-Ellison Syndrome. • In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori (H. pylori) in patients with peptic ulcer disease. See section 4.2.
This retrospective, nationwide, matched cohort study included 92 967 patients with ESRD recruited between 2000 and 2009 from the Taiwan National Health Insurance Research Database.
Sanofi and Pozen have signed an exclusive license agreement for the commercialization of Pozens' proprietary, investigational, coordinated-delivery tablets combining immediate-release...